JP2020509786A5 - - Google Patents

Download PDF

Info

Publication number
JP2020509786A5
JP2020509786A5 JP2020500024A JP2020500024A JP2020509786A5 JP 2020509786 A5 JP2020509786 A5 JP 2020509786A5 JP 2020500024 A JP2020500024 A JP 2020500024A JP 2020500024 A JP2020500024 A JP 2020500024A JP 2020509786 A5 JP2020509786 A5 JP 2020509786A5
Authority
JP
Japan
Prior art keywords
promoter
nucleic acid
seq
group
expression vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020500024A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020509786A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/022873 external-priority patent/WO2018170402A1/en
Publication of JP2020509786A publication Critical patent/JP2020509786A/ja
Publication of JP2020509786A5 publication Critical patent/JP2020509786A5/ja
Pending legal-status Critical Current

Links

JP2020500024A 2017-03-17 2018-03-16 聴覚損失の治療のための遺伝子治療構成物および方法 Pending JP2020509786A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762472790P 2017-03-17 2017-03-17
US62/472,790 2017-03-17
US201762531522P 2017-07-12 2017-07-12
US62/531,522 2017-07-12
PCT/US2018/022873 WO2018170402A1 (en) 2017-03-17 2018-03-16 Gene therapy constructs and methods for treatment of hearing loss

Publications (2)

Publication Number Publication Date
JP2020509786A JP2020509786A (ja) 2020-04-02
JP2020509786A5 true JP2020509786A5 (enExample) 2021-03-11

Family

ID=63522674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020500024A Pending JP2020509786A (ja) 2017-03-17 2018-03-16 聴覚損失の治療のための遺伝子治療構成物および方法

Country Status (10)

Country Link
US (2) US20200248203A1 (enExample)
EP (1) EP3595634B1 (enExample)
JP (1) JP2020509786A (enExample)
KR (1) KR102752457B1 (enExample)
CN (1) CN110709060A (enExample)
BR (1) BR112019019367A2 (enExample)
CA (1) CA3054941A1 (enExample)
ES (1) ES2982270T3 (enExample)
IL (1) IL268912B2 (enExample)
WO (1) WO2018170402A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12391936B2 (en) 2017-03-17 2025-08-19 Rescue Hearing, Inc. Gene therapy systems and related methods for treatment of hearing loss
CN115820654A (zh) * 2019-08-30 2023-03-21 深圳华大基因股份有限公司 Loxhd1基因突变体及其应用
IL295265A (en) * 2020-02-05 2022-10-01 Rescue Hearing Inc Gene therapy systems and related methods for treatment of hearing loss
EP4008788A1 (en) * 2020-12-03 2022-06-08 Medizinische Hochschule Hannover Lentiviral vector technology for inner ear gene therapy
CN113584082B (zh) * 2021-06-22 2023-07-25 复旦大学附属眼耳鼻喉科医院 CRISPR/Cas9基因编辑系统及其在制备治疗遗传性感音神经性聋的药物中的应用
CN113215248B (zh) * 2021-06-25 2022-04-22 中国人民解放军空军军医大学 一种感音神经性耳聋相关的myo15a基因突变检测试剂盒
WO2024259309A1 (en) * 2023-06-15 2024-12-19 Regeneron Pharmaceuticals, Inc. Gene therapy for hearing disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1280923A2 (en) * 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, a human trypsin family member and uses thereof
WO2004099779A1 (en) * 2003-05-05 2004-11-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 3 (tmprss3)
ZA200800970B (en) * 2005-08-15 2009-10-28 Genentech Inc Gene disruptions, compositions and methods relating thereto
WO2011075838A1 (en) 2009-12-21 2011-06-30 Audigen Inc. Method of treating or preventing hearing loss
US20150050354A1 (en) * 2012-04-02 2015-02-19 Moderna Therapeutics, Inc. Modified polynucleotides for the treatment of otic diseases and conditions
EP2877213B1 (en) 2012-07-25 2020-12-02 The Broad Institute, Inc. Inducible dna binding proteins and genome perturbation tools and applications thereof
US20160237455A1 (en) 2013-09-27 2016-08-18 Editas Medicine, Inc. Crispr-related methods and compositions
JP6552511B2 (ja) 2013-10-11 2019-07-31 マサチューセッツ アイ アンド イヤー インファーマリー 祖先ウイルス配列を予測する方法およびその使用
WO2015175642A2 (en) * 2014-05-13 2015-11-19 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a disease
WO2016069910A1 (en) 2014-10-29 2016-05-06 Massachusetts Eye And Ear Infirmary Methods for efficient delivery of therapeutic molecules in vitro and in vivo
JP6990182B2 (ja) * 2015-12-11 2022-02-15 マサチューセッツ アイ アンド イヤー インファーマリー 蝸牛および前庭細胞に核酸を送達するための材料および方法

Similar Documents

Publication Publication Date Title
JP2020509786A5 (enExample)
CN105408352B (zh) 通过双重aav载体有效递送大基因
CN109844124B (zh) 年龄相关疾病和病症的基因治疗方法
KR102527259B1 (ko) 스터퍼/필러 폴리누클레오티드 서열을 포함하는 벡터 및 사용 방법
AU2019250249A1 (en) Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases
AU2022201920A1 (en) Adeno-associated virus mediated delivery of C1EI as a therapy for angioedema
IL292999A (en) Compositions and methods of treating amyotrophic lateral sclerosis (als)
TW201629225A (zh) 第九因子基因療法
FI3628334T3 (fi) Geenihoito verkkokalvon pigmenttirappeuma
JPWO2019152609A5 (enExample)
JP2020054367A (ja) 改変g6pcをコードするアデノ随伴ウイルスベクターおよびその使用
JP7541027B2 (ja) 筋肉発現のためのハイブリッドプロモーター
CN113557243A (zh) 用于神经变性疾病的基因疗法
JP2017529395A5 (enExample)
CN114144518A (zh) 用于基因疗法的双亮氨酸拉链激酶抑制剂
HRP20241483T1 (hr) Sastavi i postupci za liječenje poremećaja mrežnice
JP2018536432A5 (enExample)
US20210180084A1 (en) Gene therapy vectors comprising s/mar sequences
US20250135033A1 (en) Compositions and methods for treating sialidosis
EP3302540A1 (en) Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema
KR102874560B1 (ko) 아데노연관바이러스 변이체
US12480098B1 (en) Adeno-associated virus variant
JP6473438B2 (ja) プロモーター組成物
JP2016512028A5 (enExample)
JPWO2021050991A5 (enExample)